|
Many faculty in the Department of Dermatology
have been principal investigators in pharmaceutical/biotech-sponsored
clinical trials as well as in investigator-initiated clinical and
preclinical research protocols. The general areas of interest and
expertise are very broad and include the following:
cancer (cutaneous T cell lymphoma, melanoma and nonmelanoma skin
cancer), psoriasis, contact dermatitis, atopic dermatitis, human
papilloma virus infection, HIV-related dermatoses and autoimmune
blistering diseases.
The ability to perform meaningful translational research is possible
at the Johns Hopkins dermatology department because the expertise
of our basic laboratory investigators complements these clinical
areas: keratinocyte biology (keratins, cell adhesion and barrier
function), cell signaling, photobiology, chemokines/chemotactic
models, antigen presenting cells (dendritic cells and Langerhans
cells) and antigen presentation/costimulatory molecules.
These studies are performed in space which is allocated for clinical
and preclinical studies which has a far more favorable indirect
cost structure than the more traditional NIH-funded studies.
Pediatric Dermatology
Eczema Registry and Studies
Has your child used ELIDEL cream or PROTOPIC (tacrolimus ointment)
for the treatment of eczema or atopic dermatitis? The Division of
Pediatric Dermatology at the Johns Hopkins Children's Center is
conducting for manufacturers long-time studies of the products?
safety and effectiveness. Participants receive no medications.
For more information on these observational (only) studies, contact
Jeanne Findlay in the Division of Pediatric Dermatology, 443-287-4532
or 443-287-9019.
* Parents of children between the ages of 2 and 17 who have been
diagnosed with eczema and treated with ELIDEL are invited to consider
participating in PEER (Pediatric Eczema Elective Registry) by taking
part in a bi-yearly survey conducted by Hopkins.
* Parents of children who have used PROTOPIC can participate in
a Johns Hopkins 10-year observational study sponsored by Astellas
Pharma US, Inc. Participants must have used PROTOPIC for at least
six weeks and/or have been under the age of 16 when they first used
it.
Starting in February, 2008. Parents of children age 12 years and
older whose child has been diagnosed as having mild to moderate
acne lesions may participate in an ACNE STUDY comparing two topical
acne medication
Parents of children over the age of two years who have been diagnosed
with eczema AND have had eczema herpeticum can participate in a
registry study
Long-term, observational study for children between the ages of
2 and
16 years old who have eczema and have used the drug Protopic ointment
within the last 6 months.
Long term, observational study for children between the ages of
2 and
16 years old who have eczema and have used the drug, Elidel cream
within
the last 6 months.
For a listing of melanoma and other cancer related clinical trials,
click
here
|
